Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Werno, A. M. Articles by Murdoch, D. R. Search for Related Content PubMed PubMed Citation Articles by Werno, A. M. Articles by Murdoch, D. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2003, p. 2710-2711, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2710-2711.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Antimicrobial Susceptibilities of Group B Streptococci in New Zealand

Top Letter References

 
Increasing resistance of group B Streptococcus (GBS) to clindamycin and erythromycin has been noted in many parts of the world (1-4, 6, 8-10, 12, 13, 16). Recent studies from North America have documented clindamycin and erythromycin resistance rates of 2.1 to 15% and 7.4 to 32%, respectively (1, 4, 8-10, 12, 13), and rates of 43 and 46%, respectively, have been reported in Taiwan (6).

A recent study from New Zealand noted that 15 and 7.5% of a small number of invasive GBS isolates were resistant to clindamycin and erythromycin, respectively (5). This resistance rate is surprisingly high, given that New Zealand generally has lower antimicrobial resistance rates than most of the world, and given that a recent study from Australia demonstrated an erythromycin resistance rate of only 2.8% (15).

To further evaluate GBS resistance in New Zealand, we determined the antimicrobial susceptibilities of 177 consecutive GBS strains isolated in our laboratory. The GBS strains were isolated from both invasive and mucocutaneous sites; 7 were from neonates, 10 were from children, 28 were from pregnant women, and 132 were from nonpregnant adults. Antimicrobial susceptibilities were determined by the broth microdilution method (MicroScan MICroSTREP plus; Dade Behring Inc., West Sacramento, Calif.) following guidelines recommended by the National Committee for Clinical Laboratory Standards (11). Precise MICs for resistant isolates were determined with the E test (AB Biodisk, Dalvägen, Sweden). Streptococcus agalactiae ATCC 12386 was used as a control for all antimicrobial susceptibility testing.

A summary of the antimicrobial susceptibilities of the 177 isolates tested is given in Table 1. A total of 29 isolates (16%) were resistant to clindamycin (MIC, 1 µg/ml) and/or erythromycin (MIC, 1 µg/ml). Of these 29 isolates, 19 (11%) demonstrated an unusual resistance phenotype, with low-level resistance to clindamycin (MIC, 1 to 4 µg/ml) and susceptibility to erythromycin (MIC, <0.25 µg/ml), 2 (1%) were resistant to erythromycin alone, and 8 (4%) were resistant to both clindamycin and erythromycin. No predominant serotype was seen among the isolates showing resistance to clindamycin and/or erythromycin: III-R (seven isolates), III (eight), Ia/c (two), Ia (one), Ib (two), I a/b (one), V-R (two), V (one), IV (one), R (one), and nontypeable (three).

View this table: [in this window] [in a new window]

TABLE 1. Antimicrobial susceptibilities of 177 GBS isolates

The findings of this study indicate that there is a clinically significant level of macrolide and lincosamide resistance in GBS isolates from New Zealand and confirm the findings of the smaller New Zealand study (5). The most widely documented resistance patterns are the macrolide-lincosamide-streptogramin B phenotype, conferring coresistance to erythromycin and clindamycin, and the M phenotype, conferring resistance to only erythromycin (7). In contrast to other studies, our most common resistance phenotype demonstrated resistance to only clindamycin. We performed double disk diffusion testing (14) of the isolates with this phenotype and did not demonstrate inducible resistance to erythromycin. The underlying mechanism responsible for this phenotype is unclear and is the subject of ongoing investigation.

In conclusion, GBS isolates from New Zealand exhibit rates of macrolide and lincosamide resistance similar to those in other parts of the world but differ in the distribution of resistance phenotypes. Erythromycin and clindamycin cannot be viewed as reliable alternatives for treating GBS infections in patients with penicillin allergy.

 
We acknowledge Dade Behring for providing the microdilution panels and Diana Martin, Institute of Environmental Science and Research (ESR), Porirua, New Zealand, for the serotyping of GBS isolates.

Top Letter References

 

1
1. Azavedo, J. C., M. McGavin, C. Duncan, D. E. Low, and A. McGeer. 2001. Prevalence and mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates from Ontario, Canada. Antimicrob. Agents Chemother. 45:3504-3508.[Abstract/Free Full Text]
2
2. Bland, M. L., S. T. Vermillion, D. E. Soper, and M. Austin. 2001. Antibiotic resistance patterns of group B streptococci in late third-trimester rectovaginal cultures. Am. J. Obstet. Gynecol. 184:1125-1126.[CrossRef][Medline]
3
3. De Mouy, D., J. D. Cavallo, R. Leclercq, R. Fabre, and AFORCORPI-BIO Network. 2001. Antibiotic susceptibility and mechanisms of erythromycin resistance in clinical isolates of Streptococcus agalactiae: French multicenter study. Antimicrob. Agents Chemother. 45:2400-2402.[Abstract/Free Full Text]
4
4. Fernandez, M., M. E. Hickman, and C. J. Baker. 1998. Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis. Antimicrob. Agents Chemother. 42:1517-1519.[Abstract/Free Full Text]
5
5. Grimwood, K., P. R. Stone, I. A. Gosling, R. Green, B. A. Darlow, D. R. Lennon, and D. R. Martin. 2002. Late antenatal carriage of group B Streptococcus by New Zealand women. Aust. N. Z. J. Obstet. Gynecol. 42:182-186.[CrossRef][Medline]
6
6. Hsueh, P. R., L. J. Teng, L. N. Lee, S. W. Ho, P. C. Yang, and K. T. Luh. 2001. High incidence of erythromycin resistance among clinical isolates of Streptococcus agalactiae in Taiwan. Antimicrob. Agents Chemother. 45:3205-3208.[Abstract/Free Full Text]
7
7. Leclercq, R. 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 34:482-492.[CrossRef][Medline]
8
8. Lin, F.-Y. C., P. H. Azimi, L. E. Weisman, J. B. Philips, J. Regan, P. Clark, G. G. Rhoads, J. Clemens, J. Troendle, E. Pratt, R. A. Brenner, and V. Gill. 2000. Antibiotic susceptibility profiles for group B streptococci isolated from neonates, 1995-1998. Clin. Infect. Dis. 31:76-79.[CrossRef][Medline]
9
9. Morales, W. J., S. S. Dickey, P. Bornick, and D. V. Lim. 1999. Change in antibiotic resistance of group B streptococcus: impact on intrapartum management. Am. J. Obstet. Gynecol. 181:310-314.[CrossRef][Medline]
10
10. Murdoch, D. R., and L. B. Reller. 2001. Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective. Antimicrob. Agents Chemother. 45:3623-3624.[Abstract/Free Full Text]
11
11. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 5th ed. NCCLS document M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12
12. Pearlman, M. D., C. L. Pierson, and R. G. Faix. 1998. Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. Obstet. Gynecol. 92:258-261.[CrossRef][Medline]
13
13. Rouse, D. J., W. W. Andrews, F.-Y. C. Lin, C. W. Mott, J. C. Ware, and J. B. Philips. 1998. Antibiotic susceptibility profile of group B Streptococcus acquired vertically. Obstet. Gynecol. 92:931-934.[CrossRef][Medline]
14
14. Seppälä, H., A. Nissinen, Q. Yu, and P. Huovinen. 1993. Three different phenotypes of erythromycin-resistant Streptococcus pyogenes in Finland. J. Antimicrob. Chemother. 32:885-891.[Free Full Text]
15
15. Stylianopoulos, A., N. Kelly, and S. Garland. 2002. Is penicillin and/or erythromycin resistance present in clinical isolates of group B Streptococcus in our community? Aust. N. Z. J. Obstet. Gynecol. 42:543-544.[CrossRef][Medline]
16
16. Tyrrell, G. J., L. D. Senzilet, J. S. Spika, D. A. Kertesz, M. Alagaratnem, M. Lovgren, J. A. Talbot, and the Sentinel Health Unit Surveillance System Site Coordinators. 2000. Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study. J. Infect. Dis. 182:168-173.[CrossRef][Medline]

						Anja M. Werno* Trevor P. Anderson Microbiology Unit Canterbury Health Laboratories Christchurch New Zealand David R. Murdoch Microbiology Unit Canterbury Health Laboratories Christchurch New Zealand Department of Pathology Christchurch School of Medicine and Health Sciences Christchurch New Zealand
						* Phone: 64 3 364 0347Fax: 64 3 364 0238E-mail: anja.werno{at}cdhb.govt.nz

---

Antimicrobial Agents and Chemotherapy, August 2003, p. 2710-2711, Vol. 47, No. 8
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.8.2710-2711.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Zeng, X., Kong, F., Wang, H., Darbar, A., Gilbert, G. L. (2006). Simultaneous Detection of Nine Antibiotic Resistance-Related Genes in Streptococcus agalactiae Using Multiplex PCR and Reverse Line Blot Hybridization Assay. Antimicrob. Agents Chemother. 50: 204-209 [Abstract] [Full Text]  
• Malbruny, B., Werno, A. M., Anderson, T. P., Murdoch, D. R., Leclercq, R. (2004). A new phenotype of resistance to lincosamide and streptogramin A-type antibiotics in Streptococcus agalactiae in New Zealand. J Antimicrob Chemother 54: 1040-1044 [Abstract] [Full Text]  

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Werno, A. M. Articles by Murdoch, D. R. Search for Related Content PubMed PubMed Citation Articles by Werno, A. M. Articles by Murdoch, D. R.